Advertisement

Investigational New Drugs

, Volume 31, Issue 2, pp 390–398 | Cite as

A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer

  • C. Gómez-MartínEmail author
  • R. Salazar
  • C. Montagut
  • M. Gil-Martín
  • J. A. Núñez
  • M. Puig
  • X. Lin
  • R. Khosravan
  • J. M. Tursi
  • M. J. Lechuga
  • J. Bellmunt
PHASE I STUDIES

Summary

Background This phase I, open-label, dose-escalation study examined the safety, maximum tolerated dose (MTD), and pharmacokinetics of sunitinib plus chemotherapy in patients with advanced gastric cancer. Patients and methods Sunitinib (25 or 37.5 mg/day, Schedule 2/1: 2 weeks on treatment/1 week off) plus chemotherapy (fixed starting doses of cisplatin 80 mg/m2 and 5-fluorouracil [5-FU] 4,000 mg/m2) was administered to patients with advanced gastric cancer who had not received prior therapy for metastatic disease. Results Thirty-four patients were enrolled and received sunitinib 25 mg/day (n = 24) or 37.5 mg/day (n = 10) plus chemotherapy. No dose-limiting toxicity (DLT) was reported in the sunitinib 37.5 mg cohort. However, repeated patterns of myelosuppression beyond the first cycle led to investigation of sunitinib 25 mg/day. This was the MTD, and one DLT (grade 3 mucosal inflammation) was reported. The combination had an acceptable adverse event profile; generally of grade 1/2. There was no evidence of a pharmacokinetic drug–drug interaction between sunitinib and 5-FU. Six patients (26 %) receiving the MTD had a partial response and eight patients experienced stable disease ≥3 months. Conclusions Sunitinib plus cisplatin 80 mg/m2 and 5-FU 4,000 mg/m2 were combinable and adverse events were manageable. The MTD of sunitinib was established as 25 mg/day on Schedule 2/1.

Keywords

5-fluorouracil Advanced gastric cancer Cisplatin Sunitinib 

Notes

Acknowledgments

We thank the participating patients and their families, as well as the network of investigators, research nurses, study coordinators, and operations staff. Medical writing support was provided by Nicola Crofts at ACUMED® (Tytherington, UK) and was funded by Pfizer Inc.

Funding

This study was sponsored by Pfizer Inc. Drs Bellmunt and Montagut received funding from a Fondo de Investigaciones Sanitarias (FIS) grant: ISCIII/FEDER(RD06/0020/0109

Conflicts of interest

Reza Khosravan, Maria-Jose Lechuga, Xun Lin, and Jennifer Tursi are Pfizer Inc. employees and hold Pfizer stock.

Marta Puig is a Pfizer Inc. employee.

Carlos Gómez-Martín, Ramon Salazar, Clara Montagut, Marta Gil-Martín, Juan Núñez, and Joaquim Bellmunt have no conflicts of interest to disclose.

Supplementary material

10637_2012_9830_MOESM1_ESM.pdf (36 kb)
ESM 1 (PDF 36.2 kb)

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917PubMedCrossRefGoogle Scholar
  2. 2.
    Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E (2009) Gastric cancer. Crit Rev Oncol Hematol 71:127–164PubMedCrossRefGoogle Scholar
  3. 3.
    Ajani JA (2007) Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials. Gastrointest Cancer Res 1:S16–S21PubMedGoogle Scholar
  4. 4.
    Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D’Amico TA, Das P et al (2010) Gastric cancer. J Natl Compr Canc Netw 8:378–409PubMedGoogle Scholar
  5. 5.
    Okines A, Verheij M, Allum W, Cunningham D, Cervantes A, the ESMO Guidelines Working Group (2010) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v50–v54PubMedCrossRefGoogle Scholar
  6. 6.
    Van Cutsem E, Van De Velde C, Roth A, Lordick F, Köhne CH, Cascinu S et al (2008) Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 44:182–194PubMedCrossRefGoogle Scholar
  7. 7.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997PubMedCrossRefGoogle Scholar
  8. 8.
    Drescher D, Moehler M, Gockel I, Frerichs K, Müller A, Dünschede F et al (2007) Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma–a rationale for a molecular targeting strategy? World J Gastroenterol 13:3605–3609PubMedGoogle Scholar
  9. 9.
    Zhang H, Wu J, Meng L, Shou CC (2002) Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. World J Gastroenterol 8:994–998PubMedGoogle Scholar
  10. 10.
    Muller-Tidow C, Schwable J, Steffen B, Tidow N, Brandt B, Becker K et al (2004) High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res 10:1241–1249PubMedCrossRefGoogle Scholar
  11. 11.
    Hassan S, Kinoshita Y, Kawanami C, Kishi K, Matsushima Y, Ohashi A (1998) Expression of protooncogene c-kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines. Dig Dis Sci 43:8–14PubMedCrossRefGoogle Scholar
  12. 12.
    Wagner AD, Moehler M (2009) Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol 21:381–385PubMedCrossRefGoogle Scholar
  13. 13.
    Katano M, Nakamura M, Fujimoto K, Katano M, Nakamura M, Fujimoto K et al (1998) Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma. Ann Surg 227:365–371PubMedCrossRefGoogle Scholar
  14. 14.
    Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T et al (2011) Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Canc Res 13:R66CrossRefGoogle Scholar
  15. 15.
    O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605PubMedCrossRefGoogle Scholar
  16. 16.
    Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W et al (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757–766PubMedCrossRefGoogle Scholar
  17. 17.
    Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMedGoogle Scholar
  18. 18.
    Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC et al (2006) An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070–4076PubMedCrossRefGoogle Scholar
  19. 19.
    Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471–478PubMedGoogle Scholar
  20. 20.
    Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB et al (2003) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011–1021PubMedGoogle Scholar
  21. 21.
    Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215–237PubMedCrossRefGoogle Scholar
  22. 22.
    O’Dwyer PJ, Stevenson JP, Johnson SW (2000) Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59(Suppl 4):19–27PubMedCrossRefGoogle Scholar
  23. 23.
    Houk BE, Bello CL (2011) Pharmacokinetics, modeling, and simulation in the development of Sunitinib Malate: a case study. Pharmacokinetics in Drug Development 261–84Google Scholar
  24. 24.
    Park SR, Lee K, Oh D, Park YI, Roh E, Khosravan R (2010) Sunitinib with cisplatin and capecitabine or oxaliplatin and capecitabine in advanced gastric cancer: a phase I, dose-finding study. Ann Oncol 21 (Abstract 815P)Google Scholar
  25. 25.
    Miyata Y, Muro K, Machida N, Hashigaki S, Li M, Lechuga MJ et al (2011) Phase I study of sunitinib plus S-1 and cisplatin in patients with advanced or metastatic gastric cancer. The 9th Annual Meeting of the Japanese Society of Medical Oncology, July 21–23, 2011, Yokohama, Japan (Abstract)Google Scholar
  26. 26.
    Stein HJ, Feith M, Siewert JR (2000) Cancer of the esophagogastric junction. Surg Oncol 9:35–41PubMedCrossRefGoogle Scholar
  27. 27.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Canc Inst 92:205–216CrossRefGoogle Scholar
  28. 28.
    Reck M, Frickhofen N, Cedres S, Gatzemeier U, Heigener D, Fuhr HG et al (2010) Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer 70:180–187PubMedCrossRefGoogle Scholar
  29. 29.
    Etienne MC, Chatelut E, Pivot X, Lavit M, Pujol A, Canal P et al (1998) Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer 34:92–97PubMedCrossRefGoogle Scholar
  30. 30.
    Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666–673PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • C. Gómez-Martín
    • 1
    • 2
    Email author
  • R. Salazar
    • 3
  • C. Montagut
    • 4
  • M. Gil-Martín
    • 3
  • J. A. Núñez
    • 2
  • M. Puig
    • 5
  • X. Lin
    • 6
  • R. Khosravan
    • 6
  • J. M. Tursi
    • 7
  • M. J. Lechuga
    • 7
  • J. Bellmunt
    • 4
  1. 1.Gastrointestinal Cancer Clinical Research Unit, Clinical Research Programme, Spanish National Cancer Centre (CNIO)Fuenlabrada University HospitalMadridSpain
  2. 2.Medical Oncology Division12 de Octubre University HospitalMadridSpain
  3. 3.Instituto Catala d’OncologiaL’Hospitalet Servicio de OncologiaBarcelonaSpain
  4. 4.Hospital del MarBarcelonaSpain
  5. 5.Pfizer Clinical Operations DepartmentMadridSpain
  6. 6.Pfizer OncologyLa JollaUSA
  7. 7.Pfizer Oncology, Pfizer Italia SrlMilanItaly

Personalised recommendations